Abstract 5468: Pediatric Preclinical In Vivo Testing (PIVOT) data portal enables access to 15 years of retrospective treatment study data in support of prospective study design
Authors: Acevedo Saul E. , Stearns Tim M. , Webster Phillip , Philip Vivek , Lloyd Michael W. , Srivastava Anuj , Neuhauser Steven , Begley Dale , Krupke Debbie , Jocoy Emily L. , Bult Carol J. , Chuang Jeffrey H. , Dean Dennis A. 
Published: March 2024

The PIVOT program (https://preclinicalpivot.org) is a National Cancer Institute (NCI) funded initiative in support of the RACE Act that funds collaborations between academic centers and industry partners to test the efficacy of targeted cancer treatments developed for adult oncology for potential application in diverse pediatric cancers, including cancers of the central nervous system, leukemia, osteosarcoma, sarcoma, and neuroblastoma. In support of the PIVOT program, we have harmonized more than 15 years of data collected during two previous preclinical pediatric testing programs. To disseminate the data and results of these programs broadly we designed and implemented the PIVOT Data Portal.

The PIVOT Data Portal is an R Shiny App that makes treatment efficacy data from PIVOT accessible on the web. The data are harmonized which supports comparison of treatment results across different cancer types. The data from the portal are freely available and downloadable. The portal includes study summaries within and across cancer models, statistical reports, tables, and tools for the visualization of treatment results. Data summary tables include entries for objective response measures (ORM), mean outcome, number of tumor studies, and p-value as appropriate. Visualizations include relative tumor volume plots for solid tumors; CD45 plots for leukemia; and survival curves to compare survival time across treatment groups. Treatment study visualizations and data summaries with their related metadata can be generated and downloaded within the Shiny App, allowing researchers to perform further downstream analysis.

The portal collectively contains data for 52 agents, 45 drug targets, 34 drug classes (including ADCs, small molecular inhibitors, protein degraders, BiTEs, etc.), and 167 models, with a total of 245,926 data points. Currently, 44% of agents have been tested on 2 or more cancer types. Among the solid tumor models tested, 10 had at least one treatment that resulted in an ORM of maintained complete response (MCR), while 29 leukemia models had an ORM of MCR. Similarly, 48% of agents tested had an ORM of MCR for at least one cancer type.

The PIVOT Data Portal makes pediatric cancer model treatment data available without restriction to support retrospective analyses and design of prospective studies. We are working to link cancer model data within the portal to molecular data. Merging outcome data with genomics data will facilitate computational approaches for molecular target identification, personalized treatment, and treatment optimization.

Citation Format: Saul E. Acevedo, Tim M. Stearns, Phillip Webster, Vivek Philip, Michael W. Lloyd, Anuj Srivastava, Steven Neuhauser, Dale Begley, Debbie Krupke, Emily L. Jocoy, Carol J. Bult, Jeffrey H. Chuang, Dennis A. Dean. Pediatric Preclinical In Vivo Testing (PIVOT) data portal enables access to 15 years of retrospective treatment study data in support of prospective study design [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5468.